Targeting ZBP-89 for the treatment of hepatocellular carcinoma. (3rd October 2018)

• Record Type: Journal Article
• Authors: Wang, Nuozhou; Wang, Shanshan; Yang, Sheng-li; Liu, Li-ping; Li, Ming-yue; Lai, Paul B. S.; Chen, George G.
• Is Part Of: Expert opinion on therapeutic targets. Volume 22:Number 10(2018:Oct.)
• Page Start: 817
• Page End: 822
• Publication Date: 2018-10-03
• Subjects: Apoptosis -- cancer stemness -- hepatocellular carcinoma -- transcription factor -- ZBP-89; Drugs -- Research -- Periodicals; 615.072
• DOI: 10.1080/14728222.2018.1516753
• Languages: English
• ISSNs: 1744-7631

Abstract

ABSTRACT: Introduction : Zinc-binding protein-89 (ZBP-89) is a Krüppel-type zinc-finger transcription factor that regulates target gene expression profiles via directly binding to GC-rich gene promoters, recruiting chromatin modifiers or by interacting with other proteins. The importance of ZBP-89 in the regulation of cell cycle arrest and apoptosis has led to increased interest and investigations for its role in cancer development. Areas covered : We describe ZBP-89 as a candidate therapeutic target for hepatocellular carcinoma (HCC) from several perspectives. ZBP-89 can upregulate apoptosis in HCC in a p53-dependent or – independent manner. In addition, the negative regulation of ZBP-89 on liver cancer stemness sheds light on its possible effect on sensitizing HCC to chemotherapies and the reduction of HCC relapse. The prognostic significance of ZBP-89 in HCC patients further suggests its clinical importance as a potential tumor suppressor. Expert opinion : Given the roles of ZBP-89 in HCC, we believe, ZBP-89 is a promising therapeutic target for enhancing apoptosis and diminishing the liver cancer stemness. At the same time, we also face a series of challenges, especially in the clinical implication of ZBP-89. Resolving the current controversies will advance the development of ZBP-89 for anti-HCC therapy.